Phase II Study of Pemetrexed and Erlotinib in Pretreated Nonsquamous, Non-Small-Cell Lung Cancer Patients without an EGFR mutation
- Author
- YOUNG HAK KIM1 ; NISHIMURA, Takashi1 ; OZASA, Hiroaki1 ; NAGAI, Hiroki1 ; SAKAMORI, Yuichi1 ; IWATA, Toshiyuki2 ; SUNADOME, Hironobu2 ; NISHIMURA, Tomoko2 ; MISHIMA, Michiaki1
[1] Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Japan
[2] Department of Respiratory Medicine, Kyoto Katsura Hospital, Kyoto, Japan - Source
Chemotherapy (Basel). 2013, Vol 59, Num 6, pp 414-419, 6 p ; ref : 24 ref
- CODEN
- CHTHBK
- ISSN
- 0009-3157
- Scientific domain
- Pharmacology drugs
- Publisher
- Karger, Basel
- Publication country
- Switzerland
- Document type
- Article
- Language
- English
- Author keyword
- Epidermal growth factor receptor mutation Erlotinib Non-small-cell lung cancer Pemetrexed
- Keyword (fr)
- Cancer du poumon Carcinome non petite cellule bronchopulmonaire Erlotinib Essai clinique phase II Génétique Homme Malade Mutation Pémétrexed Récepteur facteur croissance épiderme Récepteur facteur croissance Toxicité Traitement Anti-EGFR Inhibiteur de la tyrosine kinase de l'EGFR Anticancéreux Antifolate Cancer Dérivé de la quinazoline Enzyme Inhibiteur de la tyrosine kinase Inhibiteur enzyme Pathologie de l'appareil respiratoire Pathologie des bronches Pathologie des poumons Protein-tyrosine kinase Transferases Tumeur maligne
- Keyword (en)
- Lung cancer non-small cell lung carcinoma Erlotinib Phase II trial Genetics Human Patient Mutation Pemetrexed Epidermal growth factor receptor Growth factor receptor Toxicity Treatment Antineoplastic agent Antifolate Cancer Quinazoline derivatives Enzyme Tyrosine kinase inhibitor Enzyme inhibitor Respiratory disease Bronchus disease Lung disease Protein-tyrosine kinase Transferases Malignant tumor
- Keyword (es)
- Cáncer del pulmón Carcinoma no pequeňa célula bronchopulmonar Erlotinib Ensayo clínico fase II Genética Hombre Enfermo Mutación Pemetrexed Receptor del factor de crecimiento epidérmico Receptor factor crecimiento Toxicidad Tratamiento Anticanceroso Antifolato Cáncer Enzima Inhibidor tyrosine kinase Inhibidor enzima Aparato respiratorio patología Bronquio patología Pulmón patología Protein-tyrosine kinase Transferases Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B04 Tumors / 002B04C Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B11 Pneumology / 002B11A Tumors of the respiratory system and mediastinum
- Discipline
- General pharmacology Pulmonology Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 28772378
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1159/000363731 
https://dx.doi.org/10.1159/000363731
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000363731\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:130:\"Phase II Study of Pemetrexed and Erlotinib in Pretreated Nonsquamous, Non-Small-Cell Lung Cancer Patients without an EGFR mutation\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Chemotherapy (Basel)\";s:9:\"\u0000*\u0000stitle\";s:20:\"Chemotherapy (Basel)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"59\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"414\";s:8:\"\u0000*\u0000epage\";s:3:\"419\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0009-3157\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"YOUNG HAK KIM\";s:10:\"\u0000*\u0000aufirst\";s:0:\"\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:18:\"NISHIMURA, Takashi\";i:1;s:14:\"OZASA, Hiroaki\";i:2;s:13:\"NAGAI, Hiroki\";i:3;s:16:\"SAKAMORI, Yuichi\";i:4;s:16:\"IWATA, Toshiyuki\";i:5;s:18:\"SUNADOME, Hironobu\";i:6;s:17:\"NISHIMURA, Tomoko\";i:7;s:17:\"MISHIMA, Michiaki\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CHTHBK\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:130:\"Phase II Study of Pemetrexed and Erlotinib in Pretreated Nonsquamous, Non-Small-Cell Lung Cancer Patients without an EGFR mutation\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000363731\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:130:\"Phase II Study of Pemetrexed and Erlotinib in Pretreated Nonsquamous, Non-Small-Cell Lung Cancer Patients without an EGFR mutation\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Chemotherapy (Basel)\";s:9:\"\u0000*\u0000stitle\";s:20:\"Chemotherapy (Basel)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"59\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"414\";s:8:\"\u0000*\u0000epage\";s:3:\"419\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0009-3157\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"YOUNG HAK KIM\";s:10:\"\u0000*\u0000aufirst\";s:0:\"\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:18:\"NISHIMURA, Takashi\";i:1;s:14:\"OZASA, Hiroaki\";i:2;s:13:\"NAGAI, Hiroki\";i:3;s:16:\"SAKAMORI, Yuichi\";i:4;s:16:\"IWATA, Toshiyuki\";i:5;s:18:\"SUNADOME, Hironobu\";i:6;s:17:\"NISHIMURA, Tomoko\";i:7;s:17:\"MISHIMA, Michiaki\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CHTHBK\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:130:\"Phase II Study of Pemetrexed and Erlotinib in Pretreated Nonsquamous, Non-Small-Cell Lung Cancer Patients without an EGFR mutation\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000363731\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000363731\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:130:\"Phase II Study of Pemetrexed and Erlotinib in Pretreated Nonsquamous, Non-Small-Cell Lung Cancer Patients without an EGFR mutation\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Chemotherapy (Basel)\";s:9:\"\u0000*\u0000stitle\";s:20:\"Chemotherapy (Basel)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"59\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"414\";s:8:\"\u0000*\u0000epage\";s:3:\"419\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0009-3157\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"YOUNG HAK KIM\";s:10:\"\u0000*\u0000aufirst\";s:0:\"\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:18:\"NISHIMURA, Takashi\";i:1;s:14:\"OZASA, Hiroaki\";i:2;s:13:\"NAGAI, Hiroki\";i:3;s:16:\"SAKAMORI, Yuichi\";i:4;s:16:\"IWATA, Toshiyuki\";i:5;s:18:\"SUNADOME, Hironobu\";i:6;s:17:\"NISHIMURA, Tomoko\";i:7;s:17:\"MISHIMA, Michiaki\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CHTHBK\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:130:\"Phase II Study of Pemetrexed and Erlotinib in Pretreated Nonsquamous, Non-Small-Cell Lung Cancer Patients without an EGFR mutation\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000363731\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:130:\"Phase II Study of Pemetrexed and Erlotinib in Pretreated Nonsquamous, Non-Small-Cell Lung Cancer Patients without an EGFR mutation\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Chemotherapy (Basel)\";s:9:\"\u0000*\u0000stitle\";s:20:\"Chemotherapy (Basel)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"59\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"414\";s:8:\"\u0000*\u0000epage\";s:3:\"419\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0009-3157\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"YOUNG HAK KIM\";s:10:\"\u0000*\u0000aufirst\";s:0:\"\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:18:\"NISHIMURA, Takashi\";i:1;s:14:\"OZASA, Hiroaki\";i:2;s:13:\"NAGAI, Hiroki\";i:3;s:16:\"SAKAMORI, Yuichi\";i:4;s:16:\"IWATA, Toshiyuki\";i:5;s:18:\"SUNADOME, Hironobu\";i:6;s:17:\"NISHIMURA, Tomoko\";i:7;s:17:\"MISHIMA, Michiaki\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CHTHBK\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:130:\"Phase II Study of Pemetrexed and Erlotinib in Pretreated Nonsquamous, Non-Small-Cell Lung Cancer Patients without an EGFR mutation\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000363731\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:130:\"Phase II Study of Pemetrexed and Erlotinib in Pretreated Nonsquamous, Non-Small-Cell Lung Cancer Patients without an EGFR mutation\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Chemotherapy (Basel)\";s:9:\"\u0000*\u0000stitle\";s:20:\"Chemotherapy (Basel)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"59\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"414\";s:8:\"\u0000*\u0000epage\";s:3:\"419\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0009-3157\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"YOUNG HAK KIM\";s:10:\"\u0000*\u0000aufirst\";s:0:\"\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:18:\"NISHIMURA, Takashi\";i:1;s:14:\"OZASA, Hiroaki\";i:2;s:13:\"NAGAI, Hiroki\";i:3;s:16:\"SAKAMORI, Yuichi\";i:4;s:16:\"IWATA, Toshiyuki\";i:5;s:18:\"SUNADOME, Hironobu\";i:6;s:17:\"NISHIMURA, Tomoko\";i:7;s:17:\"MISHIMA, Michiaki\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CHTHBK\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:130:\"Phase II Study of Pemetrexed and Erlotinib in Pretreated Nonsquamous, Non-Small-Cell Lung Cancer Patients without an EGFR mutation\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
